Opinion|Videos|October 19, 2026
Barriers to Access – Screening, Step Therapy, and the Pharmacist's Role
Justin Arnall, Breanna Taylor, and Jeff Goff examine how step therapy, prior authorizations, and logistical hurdles delay IV iron treatment, and where pharmacists can intervene to secure overrides and streamline access for patients.
Advertisement
Episodes in this series
Justin Arnall, Breanna Taylor, and Jeff Goff examine how step therapy, prior authorizations, and logistical hurdles delay IV iron treatment, and where pharmacists can intervene to secure overrides and streamline access for patients.
Advertisement
Related to this article
After initial breast cancer treatment, pharmacists can help patients navigate ongoing endocrine therapy, manage persistent adverse effects, and address medication concerns that affect long-term care.
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
Finerenone in Heart Failure: Evidence and Practice a Year Later
3
Breast Cancer Treatment Ends, But The Medication Questions Don’t
4
Pelacarsen, Ziltivekimab Miss CV End Points: What to Know
5